xtant medical (nyse mkt: xtnt) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. with core competencies in both biologic and non-biologic surgical technologies, xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. for further information, please visit xtantmedical.com.
Company profile
Ticker
XTNT
Exchange
Website
CEO
Sean Browne
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Bacterin International Holdings, Inc., K KITZ INC
SEC CIK
Corporate docs
Subsidiaries
Bacterin International, Inc. • Surgalign SPV, Inc. • X-spine Systems, Inc. • Xtant Medical, Inc. • RTI Surgical Holdings Luxembourg SARL • Surgalign UK Limited • RTI Surgical – Singapore Pte. Ltd. • Paradigm Spine GmbH • Fourth Dimension Spine GmbH • Pioneer Surgical Technology ...
IRS number
205313323
XTNT stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
9 Apr 24
S-3
Shelf registration
1 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million
1 Apr 24
8-K
Entry into a Material Definitive Agreement
7 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Xtant Medical Announces Record Third Quarter Revenue of $25 Million
9 Nov 23
8-K/A
Financial Statements and Exhibits
26 Oct 23
8-K
Xtant Medical Announces Acquisition of nanOss Production Operations from RTI Surgical
23 Oct 23
8-K
Changes in Registrant's Certifying Accountant
18 Aug 23
Transcripts
XTNT
Earnings call transcript
2023 Q4
1 Apr 24
XTNT
Earnings call transcript
2023 Q3
9 Nov 23
XTNT
Earnings call transcript
2023 Q2
1 Aug 23
XTNT
Earnings call transcript
2023 Q1
4 May 23
XTNT
Earnings call transcript
2022 Q4
7 Mar 23
XTNT
Earnings call transcript
2022 Q3
3 Nov 22
XTNT
Earnings call transcript
2022 Q2
6 Aug 22
XTNT
Earnings call transcript
2022 Q1
8 May 22
XTNT
Earnings call transcript
2021 Q4
8 Mar 22
XTNT
Earnings call transcript
2021 Q3
12 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.75 mm | 8.75 mm | 8.75 mm | 8.75 mm | 8.75 mm | 8.75 mm |
Cash burn (monthly) | (no burn) | 737.83 k | (no burn) | (no burn) | 1.28 mm | 907.33 k |
Cash used (since last report) | n/a | 5.06 mm | n/a | n/a | 8.77 mm | 6.22 mm |
Cash remaining | n/a | 3.69 mm | n/a | n/a | -16.70 k | 2.53 mm |
Runway (months of cash) | n/a | 5.0 | n/a | n/a | -0.0 | 2.8 |
Institutional ownership, Q2 2023
62.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 1 |
Closed positions | 4 |
Increased positions | 3 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 75.48 bn |
Total shares | 81.76 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Orbimed Advisors | 73.11 mm | $67.99 bn |
Altium Capital Management | 6.23 mm | $5.79 bn |
Vanguard | 1.28 mm | $1.19 bn |
Renaissance Technologies | 597.01 k | $555.00 k |
Crescent Grove Advisors | 262.02 k | $243.66 mm |
Bridgeway Capital Management | 114.50 k | $106.47 mm |
Midwest Professional Planners | 40.74 k | $37.89 mm |
Citadel Advisors | 27.11 k | $25.21 mm |
Two Sigma Securities | 25.24 k | $23.47 mm |
STT State Street | 23.67 k | $22.01 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Apr 24 | Scott C Neils | Common Stock | Grant | Acquire A | No | No | 0 | 177,551 | 0.00 | 664,423 |
3 Apr 24 | Mark A. Schallenberger | Common Stock | Grant | Acquire A | No | No | 0 | 177,551 | 0.00 | 382,695 |
3 Apr 24 | Sean E Browne | Common Stock | Grant | Acquire A | No | No | 0 | 731,632 | 0.00 | 2,306,990 |
3 Apr 24 | Kevin D Brandt | Common Stock | Grant | Acquire A | No | No | 0 | 184,209 | 0.00 | 1,000,069 |
16 Jan 24 | Scott C Neils | Common Stock | Payment of exercise | Dispose F | No | No | 1.09 | 7,986 | 8.70 k | 486,872 |